Free Trial
NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

BioCardia logo
$2.85 -0.29 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$2.93 +0.08 (+2.81%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioCardia Stock (NASDAQ:BCDA)

Key Stats

Today's Range
$2.63
$2.99
50-Day Range
$1.75
$3.14
52-Week Range
$1.63
$6.15
Volume
115,467 shs
Average Volume
284,214 shs
Market Capitalization
$13.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Strong Buy

Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

BioCardia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

BCDA MarketRank™: 

BioCardia scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioCardia has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioCardia has received no research coverage in the past 90 days.

  • Read more about BioCardia's stock forecast and price target.
  • Earnings Growth

    Earnings for BioCardia are expected to grow in the coming year, from ($3.52) to ($1.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCardia is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCardia is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BioCardia's valuation and earnings.
  • Percentage of Shares Shorted

    1.08% of the float of BioCardia has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCardia has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCardia has recently decreased by 24.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioCardia does not currently pay a dividend.

  • Dividend Growth

    BioCardia does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.08% of the float of BioCardia has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCardia has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCardia has recently decreased by 24.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioCardia has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for BioCardia this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added BioCardia to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $136,999.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.57% of the stock of BioCardia is held by institutions.

  • Read more about BioCardia's insider trading history.
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

BCDA Stock News Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More Headlines

BCDA Stock Analysis - Frequently Asked Questions

BioCardia's stock was trading at $2.18 at the beginning of the year. Since then, BCDA shares have increased by 35.1% and is now trading at $2.9450.
View the best growth stocks for 2025 here
.

BioCardia, Inc. (NASDAQ:BCDA) issued its quarterly earnings results on Wednesday, March, 26th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.62. The firm earned $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.
Read the conference call transcript
.

BioCardia's stock reverse split on the morning of Thursday, May 30th 2024. The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

BioCardia (BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

Top institutional shareholders of BioCardia include Brown Advisory Inc. (0.76%). Insiders that own company stock include Peter Altman, Simon H Stertzer, Bill Facteau, Edward M Gillis and David Mcclung.
View institutional ownership trends
.

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC).

Company Calendar

Last Earnings
3/26/2025
Today
5/01/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCDA
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+696.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,570,000.00
Net Margins
-1,999.77%
Pretax Margin
-10,876.05%

Debt

Sales & Book Value

Annual Sales
$58,000.00
Price / Cash Flow
N/A
Book Value
($1.11) per share
Price / Book
-2.83

Miscellaneous

Free Float
3,667,000
Market Cap
$14.70 million
Optionable
Optionable
Beta
1.21
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BCDA) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners